Efficacy of biodentine as a direct pulp capping agent in reversible pulpitis.

Objective: To determine the efficacy of Biodentine as a direct pulp capping agent in reversible pulpitis. Study Design: Longitudinal Observational study. Setting: Department of Operative Dentistry, Ibn-e-Siena Hospital Multan. Period: 25th July 2023 to 24th January 2024. Methods: A total of 114 patients, aged 18-55 years with reversible pulpitis in permanent teeth were selected through consecutive sampling. Patients with irreversible pulp conditions, developmental anomalies, or handicaps were excluded. Pain was assessed using a visual analogue scale (VAS), and direct pulp capping with Biodentine was performed under local anesthesia. Efficacy was determined 24 hours post-procedure, defined as no pain (VAS=0). Data were analyzed using SPSS version 23. Descriptive statistics were run and factors influencing efficacy were assessed through Fischer’s exact at 5% significance level. Results: The mean age of participants was 27.4 ± 9.3 years, with 57% males. Pre-operatively, 76.3% had mild pain. Post-operatively, 89.5% of patients reported no pain, with only 10.5% experiencing mild pain. Efficacy was significantly higher in patients ≤25 years (98.5%) compared to >25 years (77.6%, p<0.001) and in those with mild to moderate pre-operative pain (98.9% and 65%, respectively) versus severe pain (42.9%, p<0.001). Conclusion: Direct pulp capping with Biodentine was highly effective in managing reversible pulpitis, particularly in younger patients and those with mild to moderate pre-operative pain. Age and pre-operative pain severity significantly influenced treatment outcomes.